Indivior PLC

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in North Chesterfield, VA.

Indivior PLC (OTCPK:INVVY) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Mark Crossley - CEO Ryan Preblick - CFO Dr. Christian Heidbreder - Chief Scientific Officer Jason Thompson - VP, IR Conference Call Participants James Vane-Tempest - Jefferies Thibault Boutherin - Morgan Stanley Max Herrmann - Stifel Jason Thompson Thanks, Sandra, and good morning, everyone, and welcome to our call to discuss our third quarter results. Before we begin, I need to remind you that today's comments include forward-looking statements, and that actual results may differ materially.

Indivior PLC (INVVY) Q3 2023 Earnings Call Transcript

Indivior PLC (INDV) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.30 per share. This compares to earnings of $0.29 per share a year ago.

Indivior PLC (INDV) Tops Q3 Earnings and Revenue Estimates

SLOUGH, United Kingdom and RICHMOND, Va. , Nov. 9, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending September 30, 2023.

Indivior Announces Q3 2023 Financial Results

Drugmaker Indivior PLC (LSE:INDV) has agreed to a $385 million settlement over allegations of illegally hindering generic competition for its opioid addiction drug, Suboxone. Following the announcement, Indivior's shares rose 4% as the deal signalled the conclusion of prolonged lawsuits tied to Suboxone, previously a top-selling treatment for additiction.

Indivior's $385m settement heads off prolonged court action; shares up 4%

Drugmaker Indivior said on Monday it will pay $385 million to settle a lawsuit brought by direct purchasers on claims it illegally suppressed generic competition for its opioid addiction treatment Suboxone.

Indivior to pay $385 mln to end Suboxone monopoly lawsuits

- Alar's Lead Asset ALA-1000 Potentially is the First Three-Month LAI Treatment for OUD - RICHMOND, Va., Oct. 11, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV), a leading addiction treatment company, today announced that it has gained exclusive global rights to develop, manufacture, and commercialize Alar Pharmaceuticals Inc.'s ("Alar") portfolio of long-acting injectable formulations that release a prodrug1 of buprenorphine at varying durations, including its lead long-acting injectable ("LAI") candidate, ALA-1000.

Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals

Rates of non-fatal overdose events following SUBLOCADE treatment was lower compared to daily opioid agonist therapy. Data published in the Journal of Addition Medicine RICHMOND, Va.

Indivior Publishes Real World Data Showing SUBLOCADE® May Reduce Non-Fatal Overdoses Among Individuals with Opioid Use Disorder in Canada

NEW YORK--(BUSINESS WIRE)--Click Therapeutics announces exclusive multi-product agreement with Indivior to develop and commercialize prescription digital therapeutics in SUD.

Click Therapeutics Announces Collaboration with Indivior to Develop and Commercialize Novel Prescription Digital Therapeutics in Substance Use Disorders

Indivior PLC (INDV) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Indivior PLC (INDV) is on the Move, Here's Why the Trend Could be Sustainable

Indivior has agreed to pay $30 million to settle a class action lawsuit filed in a U.S. court by health plans accusing the drugmaker of illegally suppressing generic competition for its opioid addiction treatment Suboxone.

Indivior to pay $30 million to settle health plans' Suboxone claims

RICHMOND, Va. , Aug. 21, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV), a leading addiction treatment company, announced that its subsidiary, Indivior Inc. (the "Company"), has reached an agreement ("Agreement") to resolve the claims brought by the end payor class of litigants ("the End Payor Claimants") in the In re Suboxone Antitrust Litigation multi-district litigation ("MDL").

Indivior Reaches Agreement with End Payor Class to Resolve Their Antitrust Multi-District Litigation Claims

SLOUGH, United Kingdom, and RICHMOND, Va. , July 27, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending June 30, 2023.

Indivior Announces Q2/H1 2023 Financial Results

RICHMOND, Va. , June 14, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced the acceptance of four abstracts for presentation at the 85th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD) taking place June 17-21, 2023, in Denver, Colorado.

Indivior Announces Four Abstracts Accepted for Presentation at the 85th Annual Scientific Meeting of the College on Problems of Drug Dependence

Company to Ring Opening Bell June 14 to Bring Awareness to Addiction Treatment;  Company Will Maintain Premium Listing on London Stock Exchange RICHMOND, Va. , June 12, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV), a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses, today announces that the U.S. Securities & Exchange Commission (SEC) declared its registration statement on Form 20-F effective on June 9.

Indivior to Commence Trading on Nasdaq

News for Indivior PLC Stock (INDV)